Hoffmann-La Roche Inc, the US arm of the Swiss pharmaceutical group Roche Holding, has announced the availability in California, USA, of a drug testing service that will help the law enforcement community build cases in court against criminals who deliberately misuse one of its products, Rohypnol (flunitrazepam).
The company said that its officials were in California last week initiating meetings with the law enforcement and drug abuse experts regarding the testing capability. Rohypnol is not marketed in the USA, but is prescribed elsewhere for the treatment of severe and debilitating sleeping disorders.
"The screening assays used in this testing program were developed to detect a wide range of benzodiazepines," said Salvatore Salamone, senior director of product R&D, Roche Diagnostics Systems Inc, who invented and developed many of the drug technologies currently used by Roche. Roche is also providing educational material and overdose guidelines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze